New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
08:41 EDTANIPANI Pharmaceuticals fundamentals appear on track, says Roth Capital
After ANI's stock came under considerable pressure, Roth Capital spoke with the company's management and thinks the company's fundamentals remain on track. The firm believes that the company's revenue and EPS could beat expectations, and it reiterates a Buy rating on the stock.
News For ANIP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
08:57 EDTANIPANI Pharmaceuticals price target raised to $65 from $55 at Roth Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use